anti interferon α β receptor subunit 1 ifnar1 blocking antibody  (Bio X Cell)

Journal: mBio

Article Title: Metformin as antiviral therapy protects hyperglycemic and diabetic patients

doi: 10.1128/mbio.00634-25

Figure Lengend Snippet: Treatment effectiveness of metformin against lethal SFTSV infection in BKS-db/db mice. ( A ) Survival curves of metformin- or vehicle-treated BKS-db/bd mice ( n = 10 per group) that were pretreated with anti-IFNAR1 IgG antibody and infected with SFTSV (4 × 10 4 PFU per mouse). The Kaplan-Meier method was used to analyze time-to-event data. ( B–E ) Viral loads in serum ( B ), spleen ( C ), liver ( D ), and lung ( E ) from SFTSV-infected SK-db/bd mice with or without (control group) metformin treatment at 5 days post-infection (dpi) ( n = 6 per group). Data were presented as mean ± s.d. The two-sided P values were examined using Student’s t test. ( F ) Representative hematoxylin and eosin (H&E) images from three biologically independent samples of spleen, liver, and lung sections from SFTSV-challenged BKS-db/bd mice with or without metformin treatment at 5 dpi. Scare bar: 500 µm. ( G, H ) Liver ( G ) and spleen samples ( H ) from SFTSV-challenged BKS-db/bd mice with or without metformin treatment at 5 dpi were analyzed by immunoblotting with the indicated antibodies ( n = 3 biologically independent samples).

Article Snippet: To evaluate the antiviral effect of metformin, a lethal mouse model was established using an anti-interferon α/β receptor subunit 1 (IFNAR1) blocking antibody (Bio X Cell, Cat. BE0241) pretreatment ( ).

Techniques: Infection, Control, Western Blot

Journal: Science Advances

Article Title: CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus

doi: 10.1126/sciadv.adg6856

Figure Lengend Snippet: ( A ) Serum and spleen viral titers in SFTSV-infected CCR2 −/− and WT C57BL/6J mice (four for each group) tested by immunological focus assay at 3 and 5 dpi. ( B and C ) Survival probability (B) and relative body weight (C) in anti-IFNAR1 antibody–pretreated CCR2 −/− ( n = 11) and WT ( n = 11) C57BL/6J mice after intraperitoneal infection with SFTSV. ( D ) Viral titers in serum, spleen, liver, and lung samples from anti-IFNAR1 antibody–pretreated CCR2 −/− and WT C57BL/6J mice (four for each group) tested by immunological focus assay at 3 and 5 dpi. ( E and F ) Representative images of spleen, liver, and lung sections collected at 5 dpi from control and SFTSV-challenged CCR2 −/− and WT C57BL/6J mice stained with a rabbit polyclonal antibody against SFTSV NP (E) or with hematoxylin and eosin (F). ( G ) Viral titers in serum from anti-IFNAR1 antibody–pretreated C57BL/6J mice tested by immunological focus assay at 3 ( n = 13 for each group) and 5 ( n = 10 for nontreated group and n = 13 for treated group) dpi. ( H ) Survival probability in anti-IFNAR1 antibody–pretreated C57BL/6J mice with SFTSV infection in the absence ( n = 13) or presence ( n = 13) of CCR2 antagonist RS102895 and without SFTSV infection ( n = 5). Two-tailed Student’s t test was performed for comparison of variables between two groups [(A), (B), (D), and (G)]. The Kaplan-Meier method was used to analyze time-to-event data [(C) and (H)].

Article Snippet: A lethal mouse model was also established by using an anti–interferon α/β receptor subunit 1 (IFNAR1) blocking antibody (Bio X Cell, catalog no. BE0241) pretreatment to evaluate the pathogenesis of SFTSV infection ( ).

Techniques: Infection, Control, Staining, Two Tailed Test, Comparison